Aims

The Primary Aims are to characterize and compare regimens HARVONI®, Viekira Pak™ and Zepatier™ on the following patient-­centered outcomes:

• treatment effectiveness (i.e., sustained viral response 12 weeks post-treatment, “SVR12”) and
• drug side (both patient reported and medical record abstracted)
• efficacy of ZEPATIER™  with RBV for 16 weeks when used in G1A patients with baseline resistance associated polymorphisms (RAPs)

The Secondary Aims are to characterize and compare regimens (HARVONI®,  Viekira Pak™, and Zepatier™) on the following outcomes:

• treatment adherence and persistence;
• amelioration of systemic HCV­‐associated symptoms post-­treatment;
• post-­treatment progression and regression of liver disease
• persistence of viral cure for 3 years post-treatment; and
• functional status on treatment and after
• impact of baseline NS5A RAPs on treatment outcomes